A. Provisional low-risk: D19MRD ≥ 0.1%; B. Provisional intermediate-risk: D19MRD ≥ 0.01%;
Subjects in the sytudy group or their guardians must be able to understand and accept the informed consent approved by the Ethics Committee
You may not be if
sIgM+;
ALL evolved from chronic myeloid leukemia (CML);
Down's syndrome, or major congenital or hereditary disease with organ dysfunction;
Other secondary leukemias;
CNS involvement;
History of epilepsy; or convulsions within the last month;
Known underlying congenital immunodeficiency or metabolic disease;
Congenital heart disease with cardiac insufficiency;
Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression);
Initial diagnosis of high risk;
D46MRD ≥1%.
Clareo Health | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
